Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
The initial weeks often feature significantly reduced intake partly due to nausea and stomach discomfort
Semaglutide is contraindicated in patients with a personal or family history of certain types of thyroid cancer, specifically thyroid C-cell tumors such as medullary thyroid carcinoma (MTC), or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2)
Specifically, ICER indicated a benchmark annual price range for semaglutide of between $7,500 to $9,800 would make the product cost-effective
If retatrutide gains adult approval in 2026 or 2027 (Phase 3 results from the TRIUMPH program are expected in 2025 to 2026), an adolescent trial could begin enrollment by 2028 at the earliest, with results by 2030
US$ 26.64
US$ 26.22
US$ 28.22
US$ 25.18
US$ 29.78
